Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Zevra Therapeutics (ZVRA) Amortization - Deferred Charges (2016 - 2021)

Zevra Therapeutics' Amortization - Deferred Charges history spans 7 years, with the latest figure at $150000.0 for Q1 2021.

  • For Q1 2021, Amortization - Deferred Charges fell 73.73% year-over-year to $150000.0; the TTM value through Dec 2021 reached $150000.0, down 93.49%, while the annual FY2021 figure was $150000.0, 93.49% down from the prior year.
  • Amortization - Deferred Charges reached $150000.0 in Q1 2021 per ZVRA's latest filing, down from $582000.0 in the prior quarter.
  • In the past five years, Amortization - Deferred Charges ranged from a high of $675000.0 in Q4 2019 to a low of $150000.0 in Q1 2021.
  • Average Amortization - Deferred Charges over 4 years is $440692.3, with a median of $390000.0 recorded in 2018.
  • Peak YoY movement for Amortization - Deferred Charges: surged 88.2% in 2020, then crashed 73.73% in 2021.
  • A 4-year view of Amortization - Deferred Charges shows it stood at $512000.0 in 2018, then soared by 31.84% to $675000.0 in 2019, then decreased by 13.78% to $582000.0 in 2020, then tumbled by 74.23% to $150000.0 in 2021.
  • Per Business Quant, the three most recent readings for ZVRA's Amortization - Deferred Charges are $150000.0 (Q1 2021), $582000.0 (Q4 2020), and $578000.0 (Q3 2020).